On World Health Day, meet the Dutch healthtech startups that raised funding in 2025; 5 of them are hiring

After the end of Q1 2025, it’s clear that Dutch startups are entering the year with renewed strength and momentum. The fifth edition of the State of Dutch Tech report reveals that tech companies in the Netherlands raised €3.1B in venture capital over the past year—a 47 per cent increase that signals growing confidence in the Dutch innovation ecosystem.

This growth isn’t just about capital—it reflects the maturity of the ecosystem. Startups are translating scientific excellence into real-world impact, particularly in sectors like biotechnology, digital health, and medtech. Dealroom data shows that in 2025, healthtech companies raised a combined $177M (nearly €161.73M) across 10 rounds, advancing solutions that span quantum diagnostics, wearable biosensors, surgical planning, and next-gen therapeutics.

The Netherlands is not only building such companies—it’s also building the teams and infrastructure to sustain them. On this World Health Day, we bring you the list of the Dutch healthtech startups that raised funding in 2025. Some of them are hiring. Check them out below!

Note: Certain details of these startups, such as founders’ names and the funding amount, have been sourced from Dealroom.

Cortalix

HQ: Groningen

Founder/s: Herman Steen

Funding: Raised €1M

Hiring: Yes, apply here

Cortalix builds on experience in nanobody technology and Positron Emission Tomography (PET) imaging. It develops single-domain antibodies for PET imaging diagnostics, radiotherapy, and CAR-T immunotherapy. 

The company’s platform facilitates the selection, production, and application of antibody fragments as an alternative to traditional antibodies. It specialises in producing animal-free antibodies designed for efficiency and stability while reducing production time and costs.

Cortalix operates within the biomedical network of Northern Netherlands, collaborating with the LIFE Cooperative, the University of Groningen (RUG), and the University Medical Center Groningen (UMCG).

Sencure

HQ: Roden

Founder/s: Dick van Waes (CEO)

Funding: Secured €3.9M in additional funding in Series B2 round

Hiring: Yes, apply here

Sencure develops chips for medical wearable biosensors, focusing on measuring electrophysiological parameters on the human body.

The company works on solutions for remote patient monitoring and aims to reduce the impact of monitoring on daily life while increasing its effectiveness. The company addresses the needs of both healthcare providers and their customers.

Sencure originates from ItoM Medical BV, a company founded in 2018 as the medical branch of chip development company Semiconductor Ideas to the Market (ItoM) BV. In 2023, the company raised €5M to commercialise its SNCE-800 biosensor chip.

VarmX

HQ: Leiden

Founder/s: John Glasspool (CEO)

Funding: Awarded a follow-on equity investment of €15M

Hiring: Currently not hiring

VarmX is a biotech company focused on developing therapies related to blood clotting. It was founded in 2016 as a spin-off from Leiden University Medical Center by Professor Pieter Reitsma. 

The company’s lead compound, VMX-C001, is a modified recombinant blood factor X designed to treat severe bleeding and support urgent surgery in patients using oral factor Xa inhibitors. 

VarmX has raised funding through multiple investment rounds, including a €32M Series B round in 2020 and a €32M Series B2 round in 2023, to advance its lead programme toward regulatory approval and clinical trials.

QT Sense

HQ: Groningen

Founder/s: Prof. Dr Romana Schirhagl, Dr. Deepak Veeregowda, Hoang Nguyen

Funding: Raised €6M

Hiring: Yes, apply here

QT Sense offers Quantum Nuova, a single-cell Nano-MRI platform designed for biomedical research, enabling precise investigation of oxidative stress and its impact on various health conditions.

The company uses specially prepared nanodiamonds to interact with single cells. This allows them to measure changes in light emitted by the nanodiamonds, which reflect the activity of the cells. By tracking these changes in real-time, the startup can quickly diagnose sepsis.

They also improve personalised cancer treatment and assist with drug development for both pharmaceutical companies and academic research.

Surgical Reality

HQ: Amsterdam

Founder/s: Chris Hordijk, Mike de Boer

Funding: Amount undisclosed

Hiring: Currently not hiring

Surgical Reality has developed software that creates patient-specific 3D models from traditional 2D CT scans, aiming to improve surgical planning and reduce complications linked to anatomical variations. The software allows surgeons to interact with and adjust the model during procedures. 

The technology is in use in the Netherlands, Germany, and the US, and has supported more than 350 surgeries. Research from Erasmus MC shows improved surgical planning in over half of cases compared to using CT scans alone. 

The company is pursuing European medical device approval and developed its technology in collaboration with medical and technical experts.

Phlecs

HQ: Eindhoven

Founder/s: David Aubert, Rene Wenmekers, Peter Paul Prinsen

Funding: €40,000

Hiring: Currently not hiring

Phlecs is focused on developing new approaches for treating inflammatory skin conditions. The company was founded by former Philips Healthcare employees and a domain expert, building on 15 years of clinical and technical research in photodermatology. 

Phlecs offers a proprietary full-body Blue LED Therapy platform designed to treat skin conditions without medication or UV-related risks. The company has developed and commercialised phototherapy medical devices for use in Europe and the US.

Sirius Medical

HQ: Eindhoven

Founder/s: Bram Schermers

Funding: Secured €10M in additional scale-up funding

Hiring: Yes, apply here

Sirius Medical aims to improve care for cancer patients by delivering solutions that enable precise and efficient removal of tumours. The company’s Pintuition technology provides surgeons with real-time distance and directional navigational guidance to locate tumours accurately. 

The Sirius Pintuition surgical navigation platform enables simple, wire-free localisation for breast-conserving surgery in any hospital. With over 250 active centres and over 35,000 successful Pintuition procedures across Western Europe and the US. The Pintuition technology is both CE-marked and FDA-cleared.

Bimini Biotech

HQ: Leiden

Founder/s: Digvijay Gahtory (CEO)

Funding: Closed a €3M seed investment round

Hiring: Currently not hiring

Bimini Biotech is developing therapies targeting WASp, a protein involved in the growth of haematological cancers. The company’s technology focuses on inhibiting WASp to slow or stop cancer cell growth. 

This approach is intended for lymphoma and leukaemia subtypes that are difficult to treat, especially in patients who cannot undergo intensive therapies. 

BIMINI Biotech has shown anti-cancer effects in preclinical models and is building a portfolio of WASp modulators for use in blood cancers and autoimmune disorders.

Leyden Labs

HQ: Leiden

Founder/s: Jaap Goudsmit, Koenraad Wiedhaup, Ronald Brus

Funding: raised $70M (nearly €68M)

Hiring: Yes, apply here

Leyden Labs utilises its platform to target commonalities of viral families to protect against many viruses simultaneously as opposed to vaccines that typically protect against a specific virus variant. 

The company’s platform is built on two concepts: broad protection against known viruses, new variants, and newly emerging viruses, and protection at the gate, i.e. in the mucosa (e.g. in the nose and throat).

According to the company, its intranasal product candidates (e.g. nasal sprays) will be self-administrable, providing people with the freedom to protect themselves instantaneously from infection and prevent transmission.

Alesta Therapeutics

HQ: Leiden

Founder/s: Led by Ilan Ganot, Matthias Van Woensel, Benit Maru

Funding: Closed an oversubscribed €65M Series A funding round

Hiring: Currently not hiring

Aesta Therapeutics is a biotechnology company developing transformative small-molecule therapies for rare diseases.

The Dutch company focuses on creating novel oral treatments for underserved conditions. Its lead asset, ALE1, targets hypophosphatasia (HPP), while ALE2 is aimed at treating Charcot-Marie-Tooth (CMT) disease.